
Moderna Inc (NASDAQ:MRNA) shares are down more than 40% since the start of the year and continue to trend lower Monday.
Vaccine stocks are facing selling pressure as the COVID-19 omicron variant fades, but Moderna investors have been expressing concerns about recent stock sales from Moderna CEO Stéphane Bancel, as well as the presumed deletion of his Twitter account.